## 1 (currently amended). A compound of the formula I

wherein

R1, R2 are each independently H, F, Cl, Br,  $(C_1-C_6)$ -alkyl,  $CF_3$ ,  $OCF_3$ ,  $NO_2$ , CN,  $O-(C_1-C_6)$ -alkyl,  $COO(C_1-C_6)$ -alkyl,  $COO(C_1-C_6)$ -alkyl,  $COO(C_1-C_6)$ -alkyl or  $SO_2-(C_1-C_6)$ -alkyl;

is OH, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkyl-aryl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl or O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkyl-aryl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl and O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl radicals are optionally mono- or polysubstituted by F, Cl or Br;

X is OH, O-( $C_1$ - $C_6$ )-alkyl, NH<sub>2</sub>, NH( $C_1$ - $C_6$ )-alkyl or N(( $C_1$ - $C_6$ )-alkyl)<sub>2</sub>;

A, B, D and E are each independently CH or N, with the provise that at least one of groups A, B, D and E is N;

B, D and E are CH;

m is [[0, 1 or]] 2;

[[and]] or a pharmaceutically acceptable salt[[s]] thereof.

2 (currently amended). The compound of Claim 1 wherein:

R1, R2 are each independently H, F, Cl, Br,  $(C_1-C_6)$ -alkyl,  $CF_3$ ,  $OCF_3$ ,  $NO_2$ , CN, O- $(C_1-C_6)$ -alkyl,  $COO(C_1-C_6)$ -alkyl,  $COO(C_1-C_6)$ -alkyl,  $COO(C_1-C_6)$ -alkyl or  $SO_2-(C_1-C_6)$ -alkyl;

is OH, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkyl-aryl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl or O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkyl-aryl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl and O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl radicals are optionally mono- or polysubstituted by F, Cl or Br;

X is OH, O-( $C_1$ - $C_6$ )-alkyl, NH<sub>2</sub>, NH( $C_1$ - $C_6$ )-alkyl or N(( $C_1$ - $C_6$ )-alkyl)<sub>2</sub>;

A, B, D and E are each independently CH or N, with the provise that at least one of groups A, B, D and E is N;

## B, D and E are CH;

m is [[1 or]] 2;

[[and]] or a pharmaceutically acceptable salt[[s]] thereof.

3 (currently amended). The compound of Claim 2 wherein:

R1 is H or F;

R2 is each independently H, F, Cl, Br,  $(C_1-C_6)$ -alkyl,  $CF_3$ ,  $OCF_3$ ,  $O-(C_1-C_6)$ -alkyl,  $COO(C_1-C_6)$ -alkyl,

R3 is OH,  $(C_1-C_6)$ -alkyl,  $(C_0-C_6)$ -alkyl-aryl, O- $(C_1-C_6)$ -alkyl, O- $(C_2-C_6)$ -alkenyl or O- $(C_2-C_6)$ -alkynyl, wherein said  $(C_1-C_6)$ -alkyl,  $(C_0-C_6)$ -alkyl-aryl, O- $(C_1-C_6)$ -alkyl, O- $(C_2-C_6)$ -alkenyl and O- $(C_2-C_6)$ -alkynyl radicals are optionally mono- or polysubstituted by F, Cl or Br;

X is OH, O-( $C_1$ - $C_6$ )-alkyl, NH<sub>2</sub>, NH( $C_1$ - $C_6$ )-alkyl or N(( $C_1$ - $C_6$ )-alkyl)<sub>2</sub>;

A is N;

B, D, E are each CH;

m is [[1 or]] 2;

[[and]] or a pharmaceutically acceptable salt[[s]] thereof.

4 (currently amended). The compound of Claim 3 wherein:

R1 is H or F;

R2 is H, CI, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CF<sub>3</sub>, COO(C<sub>1</sub>-C<sub>6</sub>)-alkyl or COOH,

R3 is H or phenyl;

X is OH, O-( $C_1$ - $C_6$ )-alkyl, NH<sub>2</sub>, NH( $C_1$ - $C_6$ )-alkyl or N(( $C_1$ - $C_6$ )-alkyl)<sub>2</sub>;

A is N;

B, D, E are each CH;

m is 2;

[[and]] or a pharmaceutically acceptable salt[[s]] thereof.

5 (original). A pharmaceutical composition comprising one or more compounds of Claim 1 and a pharmaceutically acceptable carrier.

6-14 (canceled).